Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an announcement.
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group, has completed the issuance of the first tranche of its 2026 corporate bonds in mainland China. The bonds, approved for public issuance to qualified investors up to an overall cap of RMB20 billion, were issued in this tranche with a principal amount of RMB1.8 billion.
The bonds carry a three-year term and a coupon rate of 1.70% per annum, and the net proceeds will be directed toward production-related expenditures, including working capital replenishment, repayment of interest-bearing debt, and project investments. This fundraising exercise strengthens the group’s funding structure, supports ongoing operational and investment needs in the PRC pharmaceutical market, and may enhance its financial flexibility and competitive positioning, though investors are cautioned to exercise care when trading the company’s securities.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company with operations in mainland China through subsidiaries such as China Resources Pharmaceutical Commercial Group. The group focuses on pharmaceutical production, distribution, and related commercial services, targeting the Chinese healthcare and medical supply market.
Average Trading Volume: 12,409,724
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.49B
Learn more about 3320 stock on TipRanks’ Stock Analysis page.